Origenis Receives Grant to Develop New Diagnostic Tools
News Feb 29, 2012
LRRK2 inhibitors are expected to be useful for the treatment of Parkinson’s disease and other neurodegenerative disorders.
The objective of this biomarker program is the development of fluorine labelled, LRRK2 specific, CNS penetrating compounds that will be used to visualize the disease progression in animal Parkinson’s models.
Origenis receives a two-years-grant from the Leading-Edge Cluster program “m4 – Personalized Medicine and Targeted Therapies”.
SYGNIS AG Announces Completion of Relocation of its Innova Biosciences UnitNews
Move forms part of integration into SYGNIS Group.READ MORE
DataArt Joins Biotechnology Association BIO DeutschlandNews
Global technology consultancy DataArt announced today that it has joined BIO Deutschland, Germany's biotechnology industry association.READ MORE